The Sidney Kimmel Comprehensive Cancer Center
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Trials
567
Active:46
Completed:294
Trial Phases
5 Phases
Early Phase 1:23
Phase 1:168
Phase 2:226
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (511 trials with phase data)• Click on a phase to view related trials
Phase 2
226 (44.2%)Phase 1
168 (32.9%)Not Applicable
88 (17.2%)Early Phase 1
23 (4.5%)Phase 3
6 (1.2%)Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia
Not Applicable
Not yet recruiting
- Conditions
- Chronic Myelomonocytic LeukemiaChronic Neutrophilic LeukemiaMyelodysplastic SyndromesMyeloproliferative Overlap Neoplasms
- Interventions
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Target Recruit Count
- 18
- Registration Number
- NCT07071155
Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
Not Applicable
Recruiting
- Conditions
- Renal Cell Carcinoma (Kidney Cancer)
- Interventions
- Drug: 111In-XYIMSR-01
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Target Recruit Count
- 6
- Registration Number
- NCT07062549
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Phase 2
Recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-07-20
- Target Recruit Count
- 20
- Registration Number
- NCT06941857
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
The COSMYC Trial (COmbined Suppression of MYC)
Phase 2
Not yet recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: Luteinizing hormone-releasing hormone (LHRH) analogue
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-06-24
- Target Recruit Count
- 50
- Registration Number
- NCT06922318
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Proton SBRT for Spinal Metastasis
Not Applicable
Recruiting
- Conditions
- Spinal Metastasis
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-04-30
- Target Recruit Count
- 12
- Registration Number
- NCT06895564
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 113
- Next
News
No news found